Arndt Vogel

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Arndt Vogel
Oct 26, 2024, 17:07 | Insight
Arndt Vogel: ICI monotherapy is a not to missed option in HCC
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and…
Oct 23, 2024, 14:20 | Blog
Angelica Petrillo: Recently published key meta-analyses about ICIs in gastric cancer
Angelica Petrillo, Medical Doctor at Ospedale del Mare Napoli, shared a post by Arndt Vogel…
Oct 22, 2024, 14:41 | Insight
Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma, summarised by Arndt Vogel
Arndt Vogel, Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School,…
Sep 20, 2024, 17:05 | Blog
Florian Lordick: Lots of important data in gastrointestinal oncology at ESMO24
Florian Lordick, Oncologist, Professor of Medicine at University of Leipzig, shared a post on LinkedIn: "ESMO24…
Sep 17, 2024, 14:30 | Blog
Cathy Eng's highlights from ESMO24
The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at…
Sep 16, 2024, 16:31 | Societies
40 Posts Not To Miss From ESMO24 Day 3
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…
Sep 14, 2024, 17:15 | Societies
45 Posts not to miss from ESMO24 Day 1
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at…
Sep 4, 2024, 10:54 | Insight
Article of the day, September 4th, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 25, 2024, 09:39 | Insight
Neratinib with or without Immune Checkpoint Inhibitors in Fibrolamellar Carcinoma
Arndt Vogel shared a post on X: "Neratinib Alone or with Immune Checkpoint Inhibitors with…
Aug 11, 2024, 12:56 | Insight
Trastuzumab Deruxtecan in HER2–Expressing BTC - Key points by Arndt Vogel
Arndt Vogel shared a post on X: "Trastuzumab Deruxtecan in HER2–Expressing BTC published in  Journal of…
Aug 5, 2024, 01:55 | Societies
Scientific Committees at the ESMO Congress 2024
The ESMO Congress is a globally influential oncology platform that brings together clinicians, researchers, patient…
Jul 24, 2024, 08:58 | Opinion
Hepatic decompensation and mortality in HCC treated with atezo-beva
Erman Akkus, Medical Oncologist at Ankara University, shared on X about an article titled "Hepatic…
Jul 22, 2024, 15:02 | Insight
Immunotherapy use and effectiveness in Child-Pugh class B
JAMA Oncology shared a post on X about a paper titled "Immunotherapy vs Best Supportive…
Jul 19, 2024, 15:23 | Insight
MRD testing using a ctDNA to Predict Recurrence of Metastatic Colorectal Cancer
Arndt Vogel shared on X: "MRD testing using a ctDNA to Predict Recurrence of Metastatic…
Jul 9, 2024, 04:35 | Blog
Arndt Vogel: Nanoliposomal irinotecan and 5-FU in cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies
Arndt Vogel shared on X: “Now fully published Nanoliposomal irinotecan & 5-FU in cholangiocarcinoma &…
Jul 7, 2024, 10:28 | Insight
Novel cancer genes in biliary tract cancers in PSC
Arndt Vogel shared on a paper by Marit Grimsrud, et al: "Off the Press: Whole-exome…
Jul 4, 2024, 11:21 | Blog
Florian Lordick: New first-line treatment algorithm for advanced gastric cancer published in ESMO
Florian Lordick, Director of Education at ESMO, shared on LinkedIn: "New first-line treatment algorithm for…
Jul 2, 2024, 09:01 | Societies
Key points from ESMOGI24 by Arndt Vogel
ESMO GI 2024 is held in Munich, Germany, and online from June 26-29. Organized by…
Jul 2, 2024, 07:19 | Societies
25 Posts You Should Not Miss From ESMOGI24!
ESMOGI24 took place as an onsite event in Munich, Germany, from 26 to 29 June…
Jun 30, 2024, 08:07 | Societies
9 Posts You Should Not Miss From Day 3 of ESMOGI24!
ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024,…
Jun 29, 2024, 10:49 | Societies
The role of gut microbiome in cancer at ESMOGI24
ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024,…
Jun 28, 2024, 15:58 | Insight
Updates on BOT/BAL from ESMOGI24
ESMO GI 2024 is held in Munich, Germany, and online from June 26-29. Organized by…
Jun 28, 2024, 13:48 | Insight
Arndt Vogel: Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24
Arndt Vogel shared on X: "Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at…
Jun 28, 2024, 11:27 | Societies
12 Posts You Should Not Miss From Day 2 of ESMOGI24!
ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024,…
Jun 28, 2024, 08:19 | Societies
15 Posts You Should Not Miss From The 1st Day of ESMOGI24
ESMO GI 2024 is taking place as an onsite event in Munich, Germany, from 26 to 29…
Jun 27, 2024, 10:23 | Insight
ESMO announces the the ESMO GI Ambassadors
The European Society for Medical Oncology (ESMO) shared on LinkedIn: “ESMOGI24: ESMO is excited to…
Jun 27, 2024, 08:31 | Societies
Arndt Vogel: Phase I study of the PKMYT1 inhibitor lunresertib in combination with FOLFIRI
Arndt Vogel shared on X: "Phase I study of the PKMYT1 inhibitor lunresertib in combination…
Jun 27, 2024, 08:26 | Societies
Jia Liu: Great summary of biliary tract cancer and gene target therapy at ESMOGI24
Jia Liu, Translational Researcher at The Kinghorn Cancer Centre, shared on X: "Great summary of…
Jun 26, 2024, 14:17 | Blog
Analysis of post-hoc of CAIRO5
Arndt Vogel shared on X: "Prognostic value of total tumor volume in CRC liver metastases.…
Jun 26, 2024, 08:17 | Insight
Comprehensive review of colorectal cancer by Cathy Eng et al.
Arndt Vogel shared on X: "Colorectal cancer in The Lancet: comprehensive review locoregional options: SBRT…
Jun 23, 2024, 14:23 | Blog
Continuous Risk Score Predicts Waitlist and Post-Transplant Outcomes in HCC
Arndt Vogel shared on X: "Continuous Risk Score Predicts Waitlist and Post-Transplant Outcomes in HCC Despite…
Jun 21, 2024, 10:51 | Blog
Arndt Vogel: It is time to register for ILCA 2024
Arndt Vogel shared a post on X: "It is time to register for ILCA 2024…
Jun 20, 2024, 17:08 | Insight
The liver in haematologic oncologic disorders
Arndt Vogel shared on X: "The liver in haematologic oncologic disorders: Very helpful, multiple causes..…
Jun 17, 2024, 11:39 | Insight
Bot/bal in relapsed refractory MSS metastatic colorectal cancer - a quick summary
Arndt Vogel shared a post on X: "Botensilimab plus balstilimab in relapsed/refractory MSS mCRC. Phase…
Jun 15, 2024, 05:47 | Blog
Nicholas Hornstein: Cholangiocarcinoma patients post gemcitabine based treatment by Arndt Vogel et al
Nicholas Hornstein, Oncology Fellow at MD Anderson Cancer Center, shared a post on X: "Phase 2…
Jun 10, 2024, 11:27 | Insight
Arndt Vogel on a paper by D.E.W. van der Kruijssen et al.
Arndt Vogel shared a post on X: "Upfront resection vs no resection of the primary…
Jun 9, 2024, 10:17 | Insight
Arndt Vogel shares news from EASL 2O24
Arndt Vogel shared the following posts from EASL 2O24 on X: "Liver transplantation following HCC…
Jun 9, 2024, 09:06 | Insight
Arndt Vogel: EASL–EASD–EASO Clinical Practice Guidelines on MASLD
Arndt Vogel shared a post on X: “EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic…
Jun 7, 2024, 02:29 | Blog
Arndt Vogel: Lenvatinib Plus Pembrolizumab vs SOC in Previously Treated mCRC
Arndt Vogel shared a post on X: "Lenvatinib Plus Pembrolizumab vs SOC in Previously Treated mCRC…
Jun 6, 2024, 09:05 | Blog
ASCO24 trials summarized by Arndt Vogel
Arndt Vogel shared on X/Twitter: "NIVO + IPI vs LEN (90%) or SORA as 1st line…
Jun 5, 2024, 07:06 | Blog
Arndt Vogel: Great discussion by David Kuang-Fu Chang on Pancreatic Cancer
Arndt Vogel shared on X/Twitter: "New Tricks With Old Tools Across the Spectrum of Pancreatic Cancer.…
Jun 5, 2024, 02:53 | Blog
Arndt Vogel: Durable complete responses to PD-1 blockade
Nina Niu Sanford shared a post by Arndt Vogel on X/Twitter: "Truly incredible. In practice we…
May 28, 2024, 04:25 | Insight
Arndt Vogel: A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
Arndt Vogel shared on X: “A randomized phase II trial of Captem or Folfiri as…
May 17, 2024, 16:09 | Blog
Trastuzumab deruxtecan in HER2+ gastric cancer overviewed by Arndt Vogel
Arndt Vogel, managing senior consultant and professor in the Department of Gastroenterology, Hepatology and Endocrinology at…
May 7, 2024, 15:35 | Insight
Arndt Vogel: Excellent summary on precision medicine in HCC
Arndt Vogel shared on X: "Precision treatment in advanced HCC. Excellent summary on precision medicine…
Apr 18, 2024, 13:47 | Insight
Arndt Vogel: How to best manage Immune-Related Adverse Events?
Arndt Vogel, Managing Senior Consultant and Professor in the Department of Gastroenterology, Hepatology and Endocrinology…
Apr 16, 2024, 07:45 | Drugs
Arndt Vogel: Access to new medicines in Canada, Europe, and the United States
Arndt Vogel shared on X/Twitter: "Access to new medicines in Canada, Europe, and the United States:…
Apr 16, 2024, 01:34 | Insight
Arndt Vogel: Prognostic and predictive impact of sex in locally advanced Microsatellite instability (MSI) gastric or gastroesophageal junction cancer
Arndt Vogel, Managing Senior Consultant and Professor in the Department of Gastroenterology, Hepatology and Endocrinology…
Mar 25, 2024, 20:18 | Opinion
Sharlene Gill: Cholangiocarcinoma for sounding the alarm on access
Sharlene Gill shared on LinkedIn: “Thank you Arndt Vogel, Rebecca Auer, and C3 Cholangiocarcinoma for sounding the…
Feb 25, 2024, 15:01 | Insight
Arndt Vogel: Impressive and comprehensive review on BRAF mutations
Arndt Vogel shared on X/Twitter: "BRAF — a tumor-agnostic drug target with lineage-specific dependencies. Impressive…
Jan 26, 2024, 17:17 | Societies
30 Posts Not To Miss From ASCO GI24
The ASCO Gastrointestinal Cancer Symposium (GI24) took place from the 18th to the 20th of…
Oct 12, 2023, 19:25 | Blog
Arndt Vogel: I am very excited to be part of the new ESMO Journal 'ESMO Real World Data and Digital Oncology' as an associate editor.
Arndt Vogel, shared a post by Oncology Advance on X/Twitter, adding: "I am very excited…
Oct 9, 2023, 00:35 | Drugs
Arndt Vogel: Off the press: Tislelizumab vs Sorafenib as 1st line Treatment for HCC JAMA Oncology.
Arndt Vogel, made the following post on Twitter: "Off the press: Tislelizumab vs Sorafenib as 1st…
Sep 7, 2023, 22:03 | Insight
Arndt Vogel: We provide comprehensive recommendations for PDAC.
Arndt Vogel, Managing senior consultant and professor in the Department of Gastroenterology, Hepatology and Endocrinology…
Aug 17, 2023, 16:27 | Insight
Arndt Vogel: Excellent review, many open questions, Targeting cancers with KRAS-G12D mutations.
Arndt Vogel has recently shared 0n Twitter: ''Next batter up! Targeting cancers with KRAS-G12D mutations…
Aug 16, 2023, 19:43 | Drugs
Arndt Vogel: FDA approves Melphalan as a liver-directed treatment for uveal melanoma.
Arndt Vogel, Head of the GI-Cancer Center and of the Center for Personalized Medicine at…
Aug 13, 2023, 10:12 | Insight
Arndt Vogel: Red-flag signs and symptoms for earlier diagnosis of early-onset colorectal cancer!
Arndt Vogel, Head of the GI-Cancer Center and of the Center for Personalized Medicine at…
Aug 9, 2023, 21:00 | Drugs
Atezolizumab/bevacizumab for the management of HCC in 1st setting - Arndt Vogel
🔥 off the press: Atezolizumab/bevacizumab for the management of HCC in 1st setting: systematic literature…
Jul 5, 2023, 04:13 | Drugs
European Commission Grants Conditional Marketing Authorization for Futibatinib for the Treatment of Adults With Cholangiocarcinoma
In a post by Arndt Vogel on Twitter, it says, "European Commission Grants Conditional Marketing…
All: 59 Posts: 1 - 100
Special Coverage